Salute e Benessere

Nicox: Half-year liquidity contract statement with Kepler Cheuvreux

Press ReleaseNicox: Half-year liquidity contract statement with Kepler CheuvreuxJuly 11, 2023 – release at 7:30 am CETSophia Antipolis, FranceUnder the liquidity contract entered into between Nicox and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30, 2023: 304,567 shares€ 10,640.56Number of executions on buy side on semester: 128Number of executions on sell side on semester: 111Traded volume on buy side on semester: 74,584...
Nasdaq GlobeNewswire
11/07/2023

European Commission approves Roche's fixed-duration Columvi (glofitamab) for…

Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available in Europe to treat the most common and aggressive form of lymphomaApproval is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated or refractory diffuse large B-cell lymphoma 1 Columvi is given for a fixed period of time and made to be readily available, providing patients with a...
Nasdaq GlobeNewswire
11/07/2023

Pixium Vision announces the agreement to extend the maturity date of the…

Pixium Vision announces the agreement to extend the maturity date of the outstanding notes associated with the terminatedESGO financing facilityParis, France, July 11 , 2023 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that it successfully negotiated an...
Nasdaq GlobeNewswire
11/07/2023

USD 700 Billion Growth in Nutraceuticals Market Size 2023 - Industry Analysis…

Nutraceuticals Market: Overview Nutraceuticals Market: Overview Nutraceuticals is a term used to describe a product that is derived from food sources and has additional health benefits in addition to providing food's essential nutritional value. Food supplements, herbal products, and processed foods such as stews, cereals, and beverages are kept separate. These items are also used as medication and provide protection against chronic diseases. According to the NCBI, nutraceuticals are...
PR Newswire
10/07/2023

KRAS Inhibitors Market is Evolving Rapidly at a CAGR of 36% by 2032, Assesses…

Key Takeaways from the KRAS Inhibitors Market Report Key Takeaways from the KRAS Inhibitors Market Report Discover which therapies are expected to grab the major KRAS inhibitors market share @KRAS Inhibitors Market Report KRAS Inhibitors Overview KRAS is a member of the RAS superfamily of small GTP-binding proteins known as RAS-like GTPases. The oncogene rat sarcoma virus (RAS) acts as a signal transducer, influencing cell proliferation, differentiation, and survival in both...
PR Newswire
10/07/2023

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated InformationMontrouge, France, July 10, 2023 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of June 30, 2023: 149,972...
Nasdaq GlobeNewswire
10/07/2023

Alphyn Biologics Presents New Data from Phase 2a Trial Showing Significant…

- Body Surface Area (BSA) reduction of at least 50 percent - Body Surface Area (BSA) reduction of at least 50 percent - Significant improvement in Skin Infection Rating Scale (SIRS) ANNAPOLIS, Md.,July 10, 2023/PRNewswire/ -- Alphyn Biologics, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics ®, today announced new data from the first cohort of its Phase 2a clinical trial program of AB-101a, a first-in-class topical candidate for...
PR Newswire
10/07/2023

Rebuttal Letters Issued to Shareholders of NYMOX PHARMACEUTICAL CORP

WHAT: Following the distribution of a press release by Nymox Pharmaceutical Corporation (the Company) regarding a NASDAQ Hearing Delist Decision at the open of business on July 7, 2023, rebuttal letters are being issued to all Company shareholders. Access the documents at www.crnsv.com WHAT: Following the distribution of apress releaseby Nymox Pharmaceutical Corporation (the Company) regarding a NASDAQ Hearing Delist Decision at the open of business onJuly 7, 2023, rebuttal letters...
PR Newswire
10/07/2023

AMBU UPGRADES FULL-YEAR 2022/23 EARNINGS EXPECTATIONS ON THE BACK OF PRELIMINARY…

Ambu raises its expectations for EBIT margin before special items to 5 - 6% (previously 3 - 5%) for the full-year 2022/23, based on its preliminary Q3 results. For Q3 2022/23, EBIT before special items totalled DKK 91m (DKK 42m), with an EBIT-margin before special items of 7.6% (3.7%), mainly driven by a better-than-expected gross margin, based on product mix and lower distribution costs. PRELIMINARY FINANCIAL HIGHLIGHTS FOR Q3 2022/23Last year's comparative figures are stated in...
Nasdaq GlobeNewswire
10/07/2023

Ipsen – Half year statement – 2023 06 30

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHFParis (France), July 10, 2023- Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of June 30, 2023, the following resources were included to the dedicated liquidity account: 17,348 shares€3,350,842.85It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account: 12,751 shares€3,137,934.80 Between January 1 st,...
Nasdaq GlobeNewswire
10/07/2023

Ipsen - Monthly information relative to the total number of voting rights and…

Monthly information relative to the total number of voting rightsand shares composingthe share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights...
Nasdaq GlobeNewswire
10/07/2023

Groupe Casino : Bilan du contrat de liquidité au 30 juin 2023

CASINO, GUICHARD-PERRACHON Société anonyme au capital de 165 892 131,90 € Siège social : 1, Cours Antoine Guichard 42000 SAINT-ETIENNE 554 501 171 R.C.S. SAINT-ETIENNECommuniqué établissant le bilan semestriel du contrat de liquidité de la sociétéCASINO, GUICHARD-PERRACHON Au titre du contrat de liquidité confié par la société Casino, Guichard-Perrachon à Rothschild Martin Maurel, les moyens suivants figuraient au compte de liquidité à la date du30 juin 2023:175 000...
Nasdaq GlobeNewswire
10/07/2023

Guerbet: Guerbet strengthens its Executive Committee with two new appointments…

Guerbet strengthens its Executive Committee with two new appointments to accelerate its commercial and industrial developmentDan Raffi appointed Director of Commercial OperationsRaoul Bernhardt appointed Director of Industrial OperationsVillepinte, 10 July 2023:Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the strengthening of its management team with two appointments. Dan Raffi and Raoul Bernhardt have joined...
Nasdaq GlobeNewswire
10/07/2023

Laboratory Information System (LIS) Market worth $4.0 billion |…

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=232312738 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=232312738 Browse in-depth TOC on "Laboratory Information System (LIS) Market"161 - Tables46 - Figures262 - Pages Laboratory Information System (LIS) Market Scope: The integrated LIS segment is expected to be the fastest-growing laboratory information systems market, by...
PR Newswire
10/07/2023

Remote Patient Monitoring Market size worth $ 166.52 Billion, Globally, by 2030…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=254710 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=254710 Browse in-depth TOCon" Remote Patient Monitoring Market " 202 - Pages 126 – Tables 37 – Figures Remote Patient Monitoring Market Driven by Increasing Prevalence of Lifestyle Disorders, Utilization of Monitoring Devices, and Aging Population The Remote Patient Monitoring Market is...
PR Newswire
10/07/2023

Cell Analysis Market worth $33.9 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=157543946 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=157543946 Browse in-depth TOC on "Cell Analysis Market" 233 - Tables 39 - Figures 250 - Pages Cell Analysis Market Scope: The software segment is estimated to grow at the fastest pace through the forecast period Based on product & service, the global cell analysis market...
PR Newswire
10/07/2023

Aortic Aneurysm Repair Market to Reach $5.8 Billion, Globally, by 2032 at 6.1%…

Request Sample Report on Diabetic Foot Ulcer Treatment Market Analysis 2032. Allied Market Research- https://www.alliedmarketresearch.com/request-sample/89401 Request Sample Report on Diabetic Foot Ulcer Treatment Market Analysis 2032. Allied Market Research-https://www.alliedmarketresearch.com/request-sample/89401 Prime determinants of growth Growing prevalence of aortic aneurysm and technological advancement drive the growth of the global aortic aneurysm repair market...
PR Newswire
10/07/2023

Signant Health Extends the Power of Clinical Supply Management Software to the…

Relaunched as Signant SmartSignals Supplies GxP Inventory, the solution provides sponsors and contract research organizations (CROs) with efficient, comprehensive management and oversight of the end-to-end supply chain. Unlike spreadsheet-based supply chain management, the GxP Inventory solution offers centralized, full visibility of clinical trial material creation, release, and distribution activities within a single system. Available as either an Essential or Enterprise option, clinical…
PR Newswire
10/07/2023

COSRX's Best Skincare Deals Ahead of Amazon Prime Day

Still unsure of what to shop? A carefully curated list of cult and popular skincare products await, featuring all-time favorites tried and tested by over 100,000 people on Amazon alone and TikTok-viral products embraced by the entire internet. Discover COSRX's best-performing products on Amazon Prime Day 2023 (up to 50% off): Still unsure of what to shop? A carefully curated list of cult and popular skincare products await, featuring all-time favorites tried and tested by over 100,000 people…
PR Newswire
10/07/2023

Novo Nordisk A/S - share repurchase programme

Bagsværd , Denmark, 10July 2023– On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023.Under the...
Nasdaq GlobeNewswire
10/07/2023

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating…

Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July10, 2023(GLOBE NEWSWIRE) --AIM ImmunoTech Inc. (NYSE American: AIM)(“AIM”) today announced it has enrolled and dosed the first subject in the company's Phase 2 study evaluating Ampligen ®as a potential therapeutic for people with post-COVID conditions (“AMP-518”). This important study milestone follows on...
Nasdaq GlobeNewswire
10/07/2023

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational…

Enrollment progressing toward interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of study BOSTON and LONDON, July10, 2023(GLOBE NEWSWIRE) --Centessa Pharmaceuticals plc(Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced the dosing of the first subject in its registrational PRESent-2 study of SerpinPC for the treatment of hemophilia B without inhibitors...
Nasdaq GlobeNewswire
10/07/2023

LifeArc and DEBRA Austria launch £2.5 million funding call for repurposing…

LifeArc andDEBRA Austria launch £2.5millionfunding call for repurposing therapies for epidermolysis bullosaNew call for projects for treatments that could be repurposed to treat epidermolysis bullosa (EB), a life-changing and currently incurable rare skin diseasePriority focus on treatments for chronic inflammation and non-healing wounds, and resulting fibrosis and skin cancer Joint initiative is part of LifeArc's Rare Disease Translational...
Nasdaq GlobeNewswire
10/07/2023

Diabetic Foot Ulcer Treatment Market to Reach $7.4 Billion, Globally, by 2032 at…

Request Sample Report on Diabetic Foot Ulcer Treatment Market Analysis 2032. Allied Market Research- https://www.alliedmarketresearch.com/request-sample/111438 Request Sample Report on Diabetic Foot Ulcer Treatment Market Analysis 2032. Allied Market Research-https://www.alliedmarketresearch.com/request-sample/111438 Prime Determinants of Growth: The global diabetic foot ulcer treatment market is experiencing growth due to several factors, including an increase in the...
PR Newswire
10/07/2023
Altri  Comunicati